Epizyme, Inc. to Present at Upcoming Events in September

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, will participate in four upcoming events in September:

• Citi 10th Annual Biotech Conference at the Mandarin Oriental in New York on Wednesday, September 9.
• Morgan Stanley Global Healthcare Conference at the Grand Hyatt Hotel in New York. Epizyme will present on Thursday, September 17 at 5:15 p.m. ET.
• As previously announced, Epizyme will participate in ESMO’s European Cancer Congress in Vienna, Austria on Saturday, September 26. At ESMO, updated data from the ongoing Phase 1 trial of EZH2 inhibitor tazemetostat (EPZ-6438) in advanced solid tumors, including IN1-negative tumors, will be presented in a session starting at 10:30 a.m. CET. Concurrent with the release of the data, the Company plans to post the presentation on its website at www.epizyme.com.Epizyme will host a conference call and live audio webcast on Monday, September 28 at 8:00 a.m. ET to review the tazemetostat data presented at ESMO. To participate in the conference call, please dial (877) 844-6886 (domestic) or (970) 315-0315 (international) and refer to conference ID 23660411.
• Leerink Partners 4th Annual Rare Disease Roundtable at Le Parker Meridian in New York on Wednesday, September 30. Epizyme will participate in an analyst-led fireside chat at 11:05 a.m. E.T. as well as investor meetings.

Live webcasts and archived replays for the September 17 Morgan Stanley conference, September 28 ESMO recap, and September 30 Leerink Rare Disease Roundtable presentations will be available by visiting the Investor Center of the Epizyme website at www.epizyme.com.

About Epizyme, Inc.

Epizyme, Inc. is a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients. Epizyme has built a proprietary product platform that the Company uses to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. HMTs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of HMTs, making them oncogenic (cancer-causing). By focusing on the genetic drivers of cancers, Epizyme's targeted science seeks to match the right medicines with the right patients.

For more information, visit www.epizyme.com and connect with us on Twitter at @EpizymeRx.

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for Epizyme, Inc. and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties inherent in the initiation of future clinical studies or expansion of ongoing clinical studies, availability and timing of data from ongoing clinical studies, whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials, expectations for regulatory approvals, development progress of the Company’s companion diagnostics, availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements, other matters that could affect the availability or commercial potential of the Company’s therapeutic candidates or companion diagnostics and other factors discussed in the "Risk Factors" section of our Form 10-Q most recently filed with the SEC, and in our other filings from time to time with the SEC. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward- looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150831005409/en/

Media/Investors:
Epizyme, Inc.
Andrew Singer, 617-500-0712
Executive Vice President and Chief Financial Officer
[email protected]

Source: Epizyme, Inc.

You May Also Be Interested In

• Intra-Cellular Therapies (ITCI) Prices Public Offering of Common Stock
• Asset Entities Inc (ASST) Files S-3
• WRAP Technologies (WRAP) Provides Update on Operations and Timing of Q4 Report